Skip to main content
Egyptian Journal of Radiology and Nuclear Medicine

Table 3 Results of PET/CT parameters in relation to pathologic response (n = 25)

From: Predicting pathological response of locally advanced breast cancer to neoadjuvant chemotherapy: comparing the performance of whole body 18F-FDG PETCT versus DCE-MRI of the breast

 

pCR (n = 8)

Non-pCR (n = 17)

p value

Median

(Range)

Median

(range)

PET/CT Initial

     

SUV max

8.8

(5.4–16.0)

5.7

(2.1–12.9)

0.027

SUV mean

4.9

(2.7–5.7)

2.7

(1.1–6.2)

0.016

MTV

19.3

(2.4–32.0)

20.8

(5.1–128.1)

0.406

TLG

96.9

(8.7–166.4)

61.4

(9.7–584.5)

0.798

PET/CT Interim

     

SUV max

2.9

(1.4–16.0)

2.5

(1.0–7.4)

0.581

SUV mean

1.9

(1.0–10.2)

1.8

(0.7–4.0)

0731

MTV

5.2

(1.2–15.5)

7.4

(1.1–32.4)

0.407

TLG

6.1

(1.2–86.7)

17.6

(2.8–198.9)

0.490

PET/CT (baseline vs interim)

     

SUVmax regression %

70.5

(0.0–100.0)

52.0

(25.0–100.0)

0.754

SUVmean regression %

60.0

(96.2–100.0)

39.3

(0.0–84.0)

0.157

MTV % change

79.0

(47.0–100.0)

73.0

(5.0–100.0)

0.440

TLG regression %

86.0

(47.0–100.0)

82.0

(23.0–100.0)

0.588

  1. Bold means the parameter was significant p-value < 0.05
Back to article page